Category: Hepatology

All Podcast Categories
S4-29.2 - EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

S4-29.2 – EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group discusses a session that Jörn co-chaired on challenges in screening patients for fatty liver diseases. Notes touch on how time restrictions obstruct frontline treaters from offering both adequate screening and support lifestyle interventions simultaneously. The group goes on to consider the potential of dual agonists efinopegdutide and pemvidutide.

S4-E29.1 - EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results

S4-E29.1 – EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results

Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group shares their initial impressions of the first three days of the meeting. Notably, they explore Stephen Harrison’s presentation of the highly anticipated MAESTRO-NASH Phase 3 results.

S4-29 - EASL Congress 2023: Real-Time Review Part 1

S4-29 – EASL Congress 2023: Real-Time Review Part 1

Surfing NASH reports on-site coverage from EASL Congress 2023 in Vienna. Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green get together early in the morning to compare notes and takeaways from an energizing meeting.

S4-27.3 - Abstract session - NAFLD: Clinical Aspects

S4-27.3 – Abstract session – NAFLD: Clinical Aspects

This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.

S4-27.2 - Abstract session - NAFLD: Therapy

S4-27.2 – Abstract session – NAFLD: Therapy

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green continues to unpack the rich EASL Congress 2023 program by discussing abstracts and presentations of interest. The group dives deep into liver science with commentary around emerging developments in NAFLD/NASH therapeutics.

S4-27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg

S4-27.1 – Unpacking the Program with Ian Rowe and Jörn Schattenberg

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green begins to unpack the rich EASL Congress 2023 program and explore in detail presentations of interest. Specifically, the group dives into anticipations around an abstract session around diagnostics and non-invasive assessment.

S4-27 - EASL Congress 2023 Preview: Great Talks to Anticipate!

S4-27 – EASL Congress 2023 Preview: Great Talks to Anticipate!

This episode comprises three separate sessions as part of the Surfing NASH ongoing coverage of a highly anticipated EASL Congress 2023. The first two discussions feature Ian Rowe, Jörn Schattenberg, Louise Campbell and Roger Green as the group reviews their lists of abstracts to look forward to. Following is an extra-sode on the subject of AI and pathology with guests Arun Sanyal and David Kleiner.

S4-25.5 - Wrap-Up on NICE Guidance for FibroScan

S4-25.5 – Wrap-Up on NICE Guidance for FibroScan

William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance from NICE on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK. This final conversation addresses a closing question around the future of FibroScan and how NICE will have progressed on the issue over the next 18 months.

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.